(NYSEMKT: NNVC) Nanoviricides's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Nanoviricides's earnings in 2026 is -$8,125,213.On average, 4 Wall Street analysts forecast NNVC's earnings for 2026 to be -$8,627,762, with the lowest NNVC earnings forecast at -$10,229,495, and the highest NNVC earnings forecast at -$6,802,866. On average, 4 Wall Street analysts forecast NNVC's earnings for 2027 to be -$8,444,192, with the lowest NNVC earnings forecast at -$8,113,048, and the highest NNVC earnings forecast at -$8,692,551.
In 2028, NNVC is forecast to generate -$7,893,484 in earnings, with the lowest earnings forecast at -$7,583,936 and the highest earnings forecast at -$8,125,646.